Valneva SE (VALN) Net Cash Flow Growth (3y) (2024 - 2026)
Valneva SE (VALN) Net Cash Flow Growth (3y) (2024 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,725.60 Bn | 68,725.31 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,953.19 Bn | 1,953.13 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 472.73 Bn | 467.94 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 123.52 Bn | 116.27 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 69.74 Bn | 60.99 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - | - |
| 8 | Argenx Se | 56.42 Bn | 51.24 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.76 Bn | 37.76 Bn | - | - |
| 10 | Valneva SE | 850.99 Mn | 731.20 Mn | 5.38 Mn | 46.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 46.73% |
| Dec 31, 2025 | -47.46% |
| Sep 30, 2025 | 40.87% |
| Jun 30, 2025 | -22.57% |
| Mar 31, 2025 | 26.06% |
| Dec 31, 2024 | -56.36% |
| Sep 30, 2024 | 32.46% |
| Jun 30, 2024 | -35.36% |
| Mar 31, 2024 | 18.72% |